Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares OutstandingShares Outstanding
Ratios

Biofrontera (BFRI) Shares Outstanding (2020 - 2025)

Biofrontera has reported Shares Outstanding over the past 6 years, most recently at $11.6 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 114899.73% year-over-year to $11.6 million; the TTM value through Dec 2025 reached $11.6 million, up 114899.73%, while the annual FY2025 figure was $11.6 million, 114899.73% up from the prior year.
  • Shares Outstanding for Q4 2025 was $11.6 million at Biofrontera, roughly flat from $11.6 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $11.6 million in Q3 2025 and troughed at $855237.0 in Q4 2021.
  • A 5-year average of $5.1 million and a median of $5.1 million in 2024 define the central range for Shares Outstanding.
  • Biggest five-year swings in Shares Outstanding: skyrocketed 799900.0% in 2021 and later crashed 99.7% in 2025.
  • Year by year, Shares Outstanding stood at $855237.0 in 2021, then soared by 56.09% to $1.3 million in 2022, then increased by 13.68% to $1.5 million in 2023, then plummeted by 99.33% to $10129.0 in 2024, then skyrocketed by 114899.73% to $11.6 million in 2025.
  • Business Quant data shows Shares Outstanding for BFRI at $11.6 million in Q4 2025, $19881.0 in Q3 2025, and $9234.0 in Q2 2025.